HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

  • Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc VIR. The analyst maintained a Buy rating on VIR shares.
  • The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline, which includes compounds in development for chronic hepatitis B virus (CHB), human immunodeficiency virus (HIV), and influenza (flu), as among the most attractive in the entire biotech sector.
  • Furthermore, the firm believes that with cash and investments of $2.5 billion, Vir is well-capitalized to conduct the studies necessary to achieve the full value of its pipeline that e could generate peak annual revenues of at least $10 billion. 
  • Related: Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here.
  • HC Wainwright has confidence in Vir and GlaxoSmithKline Plc's GSK COVID-19 franchise and believes that the collaboration is capable of adjusting to the emerging variants of SARS-CoV-2. 
  • The updated estimates include a risk adjustment (25%) to capture the potential for Xuvudy to be re-authorized without caveats though recognizing the possibility that the program may not be able to move forward in its current form.
  • Price Action: VIR shares are up 3.67% at $19.78 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!